argenx NV ADR
USUSDargenx NV ADR (US:ARGNF) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 3. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la empresa
- Sitio web
- argenx.com
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede central
- Amsterdam, Netherlands
- Consejero delegado
- Ms. Karen Massey
- Empleados
- 1 863
- Fundada
- 2008
- Acciones en circulación
- Capital flotante
- 62.43 M
- Capitalización bursátil
- 63.2 mil M USD
- Insiders
- 0.01%
- Inversores institucionales
- 48.57%
- Industria (SIC)
- Biological Products, (No Diagnostic Substances)
- Forma jurídica
- BBEB
- ISIN
- NL0010832176
- LEI
- 7245009C5FZE6G9ODQ71
- Ratio de reparto
- 0%
- FCF
- 904 M USD
- Deuda
- 47.0 M USD0.1 a. de FCF
- Racha de dividendos
- —
Descripción
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Dividendos
No se han encontrado pagos de dividendos (comprobado el 07.10.2026). Es probable que la empresa no reparta dividendos.
Noticias de esta semana
No hay noticias en la última semana. Últimas noticias: 29.09.2026.
Principales accionistas
| Titular | Participación | Acciones | Fecha del informe |
|---|---|---|---|
| VANGUARD SPECIALIZED FUN… | 1.66% | 1.04 M | 2026-07-31 |
| VANGUARD STAR FUNDS-Vang… | 1.46% | 913 032 | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.97% | 605 295 | 2026-06-30 |
| EuroPacific Growth Fund-… | 0.81% | 506 272 | 2026-06-30 |
| iShares Trust-iShares Co… | 0.73% | 459 544 | 2026-07-31 |
| VANGUARD WORLD FUND-Vang… | 0.73% | 458 852 | 2026-05-31 |
| Fidelity Concord Street… | 0.38% | 240 592 | 2026-07-31 |
| iShares Trust-iShares MS… | 0.35% | 219 191 | 2026-07-31 |
| Franklin Custodian Funds… | 0.32% | 200 000 | 2026-06-30 |
| Fidelity Rutland Square… | 0.31% | 193 374 | 2026-07-31 |
| Prudential World Fd., In… | 0.28% | 176 138 | 2026-07-31 |
| Federated Hermes Equity… | 0.28% | 173 045 | 2026-07-31 |
| Pacer Advisors, Inc. | 0% | 794 | 2026-06-30 |
